-+ 0.00%
-+ 0.00%
-+ 0.00%

ALX ONCOLOGY ANNOUNCES POSITIVE RESULTS FROM ONGOING INVESTIGATOR-SPONSORED PHASE 2 TRIAL EVALUATING EVORPACEPT IN COMBINATION WITH STANDARD-OF-CARE TREATMENT IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA, AT ASH ANNUAL MEETING

Reuters·12/07/2025 13:00:02

Please log in to view news